CONTEXT: Endocannabinoid receptor 1 blockade is proposed to improve metabolic complications of obesity via central and peripheral effects. OBJECTIVE: Our objective was to test whether rimonabant improves insulin regulation of free fatty acid and glucose metabolism after controlling for fat loss. DESIGN: This was a double-blind, placebo-controlled substudy of the visceral fat reduction assessed by computed tomography scan on rimonabant (VICTORIA) trial. PARTICIPANTS AND SETTING:Sixty-seven abdominally obese, metabolic syndrome volunteers age 35-70 yr participated at academic medical center general clinical research centers. INTERVENTION: Intervention included a 12-month lifestyle weight management program plus rimonabant 20 mg/d or placebo. MAIN OUTCOME MEASURES: Body composition and two-step euglycemic, hyperinsulinemic clamp before and after intervention were performed. Insulin sensitivity was assessed as insulin concentration needed to suppress by 50% palmitate concentration [IC50(palmitate)], flux [IC50(palmitate)f], and hepatic glucose output [IC50(HGO)] and as insulin-stimulated glucose disposal (Δ glucose disappearance per Δ insulin concentration--glucose slope). RESULTS:Body fat decreased by 4.5±2.9% (SD) in the rimonabant and 1.9±4.5% in the placebo group (P<0.005). The primary [improvement in IC50(palmitate) and IC50(palmitate)f] and secondary [improvement in IC50(HGO) and glucose slope] outcomes were not significantly different between the rimonabant and placebo groups. Post hoc analyses revealed that 1) changes in body mass index (BMI) and IC50(palmitate) were correlated (P=0.005) in the rimonabant group; this relationship was not significantly different from placebo when controlling for greater BMI loss (P=0.5); 2) insulin-regulated glucose disposal improved in both groups (P=0.002) and correlated with changes in BMI. CONCLUSIONS: Improvements observed in insulin regulation of free fatty acid and glucose metabolism with rimonabant treatment in humans was not greater than that predicted by weight loss alone.
RCT Entities:
CONTEXT: Endocannabinoid receptor 1 blockade is proposed to improve metabolic complications of obesity via central and peripheral effects. OBJECTIVE: Our objective was to test whether rimonabant improves insulin regulation of free fatty acid and glucose metabolism after controlling for fat loss. DESIGN: This was a double-blind, placebo-controlled substudy of the visceral fat reduction assessed by computed tomography scan on rimonabant (VICTORIA) trial. PARTICIPANTS AND SETTING: Sixty-seven abdominally obese, metabolic syndrome volunteers age 35-70 yr participated at academic medical center general clinical research centers. INTERVENTION: Intervention included a 12-month lifestyle weight management program plus rimonabant 20 mg/d or placebo. MAIN OUTCOME MEASURES: Body composition and two-step euglycemic, hyperinsulinemic clamp before and after intervention were performed. Insulin sensitivity was assessed as insulin concentration needed to suppress by 50% palmitate concentration [IC50(palmitate)], flux [IC50(palmitate)f], and hepatic glucose output [IC50(HGO)] and as insulin-stimulated glucose disposal (Δ glucose disappearance per Δ insulin concentration--glucose slope). RESULTS: Body fat decreased by 4.5±2.9% (SD) in the rimonabant and 1.9±4.5% in the placebo group (P<0.005). The primary [improvement in IC50(palmitate) and IC50(palmitate)f] and secondary [improvement in IC50(HGO) and glucose slope] outcomes were not significantly different between the rimonabant and placebo groups. Post hoc analyses revealed that 1) changes in body mass index (BMI) and IC50(palmitate) were correlated (P=0.005) in the rimonabant group; this relationship was not significantly different from placebo when controlling for greater BMI loss (P=0.5); 2) insulin-regulated glucose disposal improved in both groups (P=0.002) and correlated with changes in BMI. CONCLUSIONS: Improvements observed in insulin regulation of free fatty acid and glucose metabolism with rimonabant treatment in humans was not greater than that predicted by weight loss alone.
Authors: S Bátkai; Z Járai; J A Wagner; S K Goparaju; K Varga; J Liu; L Wang; F Mirshahi; A D Khanolkar; A Makriyannis; R Urbaschek; N Garcia; A J Sanyal; G Kunos Journal: Nat Med Date: 2001-07 Impact factor: 53.440
Authors: Raquel Gómez; Miguel Navarro; Belén Ferrer; José M Trigo; Ainhoa Bilbao; Ignacio Del Arco; Andrea Cippitelli; Felice Nava; Daniele Piomelli; Fernando Rodríguez de Fonseca Journal: J Neurosci Date: 2002-11-01 Impact factor: 6.167
Authors: M-H Son; H D Kim; Y N Chae; M-K Kim; C Y Shin; G J Ahn; S-H Choi; E K Yang; K-J Park; H W Chae; H-S Moon; S-H Kim; Y-G Shin; S-H Yoon Journal: Int J Obes (Lond) Date: 2009-12-22 Impact factor: 5.095
Authors: Joseph Tam; V Kiran Vemuri; Jie Liu; Sándor Bátkai; Bani Mukhopadhyay; Grzegorz Godlewski; Douglas Osei-Hyiaman; Shinobu Ohnuma; Suresh V Ambudkar; James Pickel; Alexandros Makriyannis; George Kunos Journal: J Clin Invest Date: 2010-07-26 Impact factor: 14.808
Authors: Douglas Osei-Hyiaman; Jie Liu; Liang Zhou; Grzegorz Godlewski; Judith Harvey-White; Won-il Jeong; Sándor Bátkai; Giovanni Marsicano; Beat Lutz; Christoph Buettner; George Kunos Journal: J Clin Invest Date: 2008-09 Impact factor: 14.808
Authors: Jeanine B Albu; Leonie K Heilbronn; David E Kelley; Steven R Smith; Koichiro Azuma; Evan S Berk; F Xavier Pi-Sunyer; Eric Ravussin Journal: Diabetes Date: 2009-12-22 Impact factor: 9.461
Authors: N Perwitz; J Wenzel; I Wagner; J Büning; M Drenckhan; K Zarse; M Ristow; W Lilienthal; H Lehnert; J Klein Journal: Diabetes Obes Metab Date: 2009-11-05 Impact factor: 6.577
Authors: Kazanna C Hames; Maria Morgan-Bathke; Debra A Harteneck; Lendia Zhou; John D Port; Ian R Lanza; Michael D Jensen Journal: Am J Clin Nutr Date: 2017-04-19 Impact factor: 7.045
Authors: Vidya Vaidyanathan; Raul A Bastarrachea; Paul B Higgins; V Saroja Voruganti; Subhash Kamath; Nicholas V DiPatrizio; Daniele Piomelli; Anthony G Comuzzie; Elizabeth J Parks Journal: Am J Physiol Endocrinol Metab Date: 2012-07-03 Impact factor: 4.310
Authors: Andrea Siebenhofer; Sebastian Winterholer; Klaus Jeitler; Karl Horvath; Andrea Berghold; Cornelia Krenn; Thomas Semlitsch Journal: Cochrane Database Syst Rev Date: 2021-01-17
Authors: Ranganath Muniyappa; Sara Sable; Ronald Ouwerkerk; Andrea Mari; Ahmed M Gharib; Mary Walter; Amber Courville; Gail Hall; Kong Y Chen; Nora D Volkow; George Kunos; Marilyn A Huestis; Monica C Skarulis Journal: Diabetes Care Date: 2013-03-25 Impact factor: 19.112